v ::INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES::
ResearcherID - CLICK HERE Scientific Journal Impact Factor (SJIF-2020) - CLICK HERE

TITLE:

COMPARISON OF THERAPEUTIC ROLE OF N. SATIVA SEEDS WITH LEUKOTRIENE RECEPTOR BLOCKER MONTELUKAST AMONG PERIODIC ALLERGIC RHINITIS PATIENTS

AUTHORS:

Dr Aiza Chaudhary, Dr Mariya Jamil Owaisi, Dr Aqsa Mumtaz

ABSTRACT:

Objective: The study was held for comparing the therapeutic role of N. Sativa seeds with leukotriene receptor blocker Montelukast in patients with periodic allergic rhinitis. Methods: We carried out this research at Jinnah Hospital, Lahore from October 2017 to June 2018. A total number of forty-seven participants who were patients of seasonal allergic rhinitis and looking for outpatient administration were evaluated through comparative uncontrolled single-blind clinical assessment. All participants belonged to different primary health care points. After the registration process, the participants were divided into a single-blind approach for obtaining Montelukast. Group A, (10 mg/day, n=24) and group B (250 mg/day of N. Sativa, n=24) verbally for fourteen days. All Patients joining up the research study had accomplished therapeutic directions. Results: An obvious as well as an early decline was observed in both of N. Sativa and Montelukast in the time of day and also as ophthalmic signs, while montelukast displayed late and moderated effects in symptoms of nighttime after comparison with N. Sativa. Additionally, montelukast is also found behind drug-associated side effects as that of heat burn, headache, and faintness. Conclusion: N. Sativa is harmless and there are no threats related to serious and hostile effects. Thus, it is found beneficial for seasonal allergic rhinitis patients as a dependable alternative method for management. Keywords: Leukotriene Receptor Blocker, Montelukast, Nigella Sativa, SAR (Seasonal Allergic Rhinitis), Central Nervous System.

FULL TEXT

Top
  • Follows us on
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.